November 13, 2017 09:57 AM ESTUpdated 11:06 AM
News Briefing

Al­ny­lam's patisir­an grabs EMA ac­cel­er­at­ed re­view; CRISPR Ther­a­peu­tics, Case­bia en­ter mR­NA deal with Cure­Vac

Amber Tong

→ Promis­ing Phase III da­ta on patisir­an have proven quite pro­duc­tive for Al­ny­lam, which an­nounced to­day that the EMA has grant­ed an

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times